Nalfurafine: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
Line 4: Line 4:
| verifiedrevid = 447928192
| verifiedrevid = 447928192
| IUPAC_name = (2''E'')-''N''-[(5α,6β)-17-(cyclopropylmethyl)- 3,14-dihydroxy- 4,5-epoxymorphinan- 6-yl]- 3-(3-furyl)- ''N''-methylacrylamide
| IUPAC_name = (2''E'')-''N''-[(5α,6β)-17-(cyclopropylmethyl)- 3,14-dihydroxy- 4,5-epoxymorphinan- 6-yl]- 3-(3-furyl)- ''N''-methylacrylamide
| image = Nalfurafine.svg
| image = Nalfurafine.png


<!--Clinical data-->
<!--Clinical data-->
Line 58: Line 58:
| StdInChIKey      = XGZZHZMWIXFATA-UEZBDDGYSA-N
| StdInChIKey      = XGZZHZMWIXFATA-UEZBDDGYSA-N
}}
}}
 
              __NOTOC__
{{SI}}
{{CMG}}
==Overview==
 
'''Nalfurafine''' ([[International Nonproprietary Name|INN]] and [[United States Adopted Name|USAN]];<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/nalfurafine_hcl.pdf Statement on a Nonproprietary Name adopted by the USAN Council]</ref> also known as AC-820, TRK-820; trade name '''Remitch''') is a [[kappa Opioid receptor|κ-opioid receptor]] [[agonist]] marketed as a treatment for [[Uremia|uremic]] [[pruritus]] in people undergoing [[hemodialysis]].<ref>{{cite web|url=http://www.acologix.com/pipeline_ac-820.html|title=AC-820|publisher=Acologix|year=2009}}</ref>
'''Nalfurafine''' ([[International Nonproprietary Name|INN]] and [[United States Adopted Name|USAN]];<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/nalfurafine_hcl.pdf Statement on a Nonproprietary Name adopted by the USAN Council]</ref> also known as AC-820, TRK-820; trade name '''Remitch''') is a [[kappa Opioid receptor|κ-opioid receptor]] [[agonist]] marketed as a treatment for [[Uremia|uremic]] [[pruritus]] in people undergoing [[hemodialysis]].<ref>{{cite web|url=http://www.acologix.com/pipeline_ac-820.html|title=AC-820|publisher=Acologix|year=2009}}</ref>


Line 67: Line 71:




{{Opioidergics}}


[[Category:Morphinans]]
[[Category:Morphinans]]
Line 76: Line 79:
[[Category:Alkenes]]
[[Category:Alkenes]]
[[Category:Furans]]
[[Category:Furans]]
[[Category:Kappa agonists]]
[[Category:Drug]]
 
 
{{dermatologic-drug-stub}}

Latest revision as of 17:01, 13 April 2015

Nalfurafine
Clinical data
SynonymsTRK-820
AHFS/Drugs.comInternational Drug Names
Routes of
administration
intravenous
ATC code
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC28H32N2O5
Molar mass476.564 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Nalfurafine

Articles

Most recent articles on Nalfurafine

Most cited articles on Nalfurafine

Review articles on Nalfurafine

Articles on Nalfurafine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Nalfurafine

Images of Nalfurafine

Photos of Nalfurafine

Podcasts & MP3s on Nalfurafine

Videos on Nalfurafine

Evidence Based Medicine

Cochrane Collaboration on Nalfurafine

Bandolier on Nalfurafine

TRIP on Nalfurafine

Clinical Trials

Ongoing Trials on Nalfurafine at Clinical Trials.gov

Trial results on Nalfurafine

Clinical Trials on Nalfurafine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Nalfurafine

NICE Guidance on Nalfurafine

NHS PRODIGY Guidance

FDA on Nalfurafine

CDC on Nalfurafine

Books

Books on Nalfurafine

News

Nalfurafine in the news

Be alerted to news on Nalfurafine

News trends on Nalfurafine

Commentary

Blogs on Nalfurafine

Definitions

Definitions of Nalfurafine

Patient Resources / Community

Patient resources on Nalfurafine

Discussion groups on Nalfurafine

Patient Handouts on Nalfurafine

Directions to Hospitals Treating Nalfurafine

Risk calculators and risk factors for Nalfurafine

Healthcare Provider Resources

Symptoms of Nalfurafine

Causes & Risk Factors for Nalfurafine

Diagnostic studies for Nalfurafine

Treatment of Nalfurafine

Continuing Medical Education (CME)

CME Programs on Nalfurafine

International

Nalfurafine en Espanol

Nalfurafine en Francais

Business

Nalfurafine in the Marketplace

Patents on Nalfurafine

Experimental / Informatics

List of terms related to Nalfurafine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Nalfurafine (INN and USAN;[1] also known as AC-820, TRK-820; trade name Remitch) is a κ-opioid receptor agonist marketed as a treatment for uremic pruritus in people undergoing hemodialysis.[2]

As of January 2010, it is also being investigated for the treatment of pruritus in patients with chronic liver disease.[3]

References

  1. Statement on a Nonproprietary Name adopted by the USAN Council
  2. "AC-820". Acologix. 2009.
  3. Clinical trial number NCT00638495 for "Phase II Study of TRK-820 Soft Capsules — Intractable Pruritus in Patients With Chronic Liver Disease" at ClinicalTrials.gov